Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.58 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MITF | O75030 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4745756 | 0.87 | EPHX2 (0.71) | EPHX2NR1H4MEN1KMT2AALDH1A1 | |
| Urea SCHEMBL4746502 | 0.85 | EPHX2 (0.65) | EPHX2NR1H4MEN1KMT2AALDH1A1 | |
| Terephthalic Acid SCHEMBL998372 | 0.84 | TSHR (0.63) | ALDH1A1CA2CA12CA9TP53 | |
| SCHEMBL7883674 | 0.82 | MAPT (0.76) | EPHX2NR1H4MEN1KMT2AALDH1A1 | |
| SCHEMBL1019968 | 0.81 | EPHX2 (0.74) | EPHX2NR1H4MEN1KMT2AALDH1A1 | |
| SCHEMBL28513066 | 0.81 | EPHX2 (0.59) | EPHX2NR1H4MEN1KMT2AALDH1A1 | |
| SCHEMBL712280 | 0.80 | SMN1; SMN2 (0.73) | EPHX2MEN1KMT2AALDH1A1CA2 | |
| SCHEMBL456985 | 0.80 | ALDH1A1 (0.70) | MEN1KMT2AALDH1A1CA2CA9 | |
| SCHEMBL2834402 | 0.80 | MITF (0.68) | MEN1KMT2AALDH1A1MITFCA2 | |
| SCHEMBL3885202 | 0.79 | EPHX2 (0.62) | EPHX2NR1H4MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243161-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-12269800-B2 | Delivery of therapeutic alkaloid compounds | SENSORIUM THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20250051277-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| US-20240246910-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2024-07-25 | — | — | US | disclosed |
| US-11999694-B2 | Delivery of therapeutic alkaloid compounds | SENSORIUM THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20230159455-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159455-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159455-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2023076586-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076586-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-4518533-A | Azetidinone-4-disulfides as intermediates for thia-aza compounds with a beta-lactam ring | CIBA GEIGY CORPORATION (US) | 1985-05-21 | — | — | US | disclosed |
| US-4515717-A | INTERMEDIATES FOR 6-UNSUBSTITUTED PENICILLIN ANTIOBIOTICS | CIBA GEIGY CORPORATION (US) | 1985-05-07 | — | — | US | disclosed |
| US-4500457-A | TREATING AN ACYLOXYAZETIDINONE WITH MERCAPTO COMPOUND, GLYOYLIC ESTER, HALOGENATION AGENT, AND PHOSPHINE COMPOUNT THEN CYCLIZATION | CIBA-GEIGY CORPORATION (US) | 1985-02-19 | — | — | US | disclosed |
| US-4447360-A | Intermediates for thia-aza compounds with a β-lactam ring | CIBA-GEIGY CORPORATION (US) | 1984-05-08 | — | — | US | disclosed |
| EP-0003960-B1 | 6-SUBSTITUTED THIA-AZA-COMPOUNDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CIBA-GEIGY AG (CH) | 1983-06-29 | — | — | EP | disclosed |
| US-4331676-A | 2-PENEM COMPOUNDS UNSUBSTITUTED IN THE 6 POSITION | CIBA-GEIGY CORPORATION (US) | 1982-05-25 | — | — | US | disclosed |
| EP-0042026-A1 | 3,4-Disubstituted azetidin-2-on compounds and process for their preparation | CIBA-GEIGY AG (CH) | 1981-12-23 | — | — | EP | disclosed |
| EP-0003960-A1 | 6-Substituted thia-aza-compounds, their preparation and pharmaceutical compositions containing them | CIBA-GEIGY AG (CH) | 1979-09-19 | — | — | EP | disclosed |
| US-3950362-A | OXABICYCLOOCTANES AND PROCESS FOR THEIR MANUFACTURE | CIBA-GEIGY CORPORATION (US) | 1976-04-13 | — | — | US | disclosed |
| US-3941813-A | Dioxatricyclodecanes and process for their manufacture | CIBA-GEIGY CORPORATION (US) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051277-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | PNMT, HNMT, NNMT | EPHX2 1841/4885NR1H4 703/4885MEN1 163/4885 |
| US-20250243161-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | PNMT, HNMT, NNMT | EPHX2 1841/4885NR1H4 703/4885MEN1 163/4885 |
| US-20230159455-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | PNMT, HNMT, NNMT | EPHX2 1841/4885NR1H4 703/4885MEN1 163/4885 |
| US-20240246910-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | PNMT, HNMT, NNMT | EPHX2 1841/4885NR1H4 703/4885MEN1 163/4885 |
| US-12269800-B2 | Delivery of therapeutic alkaloid compounds | PNMT, HNMT, NNMT | EPHX2 1841/4885NR1H4 703/4885MEN1 163/4885 |
| US-11999694-B2 | Delivery of therapeutic alkaloid compounds | PNMT, HNMT, NNMT | EPHX2 1841/4885NR1H4 703/4885MEN1 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.